LifeMD (NASDAQ:LFMD) Announces Earnings Results, Misses Estimates By $0.01 EPS

Posted by Brian Himes on Aug 6th, 2026

LifeMD (NASDAQ:LFMD – Get Free Report) announced its quarterly earnings results on Wednesday. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.01), FiscalAI reports. The business had revenue of $47.28 million for the quarter, compared to analysts’ expectations of $49.16 million. LifeMD had a net margin of 2.37% and a negative return on equity of 150.88%.

Here are the key takeaways from LifeMD’s conference call:

Q2 profitability missed expectations: Revenue was $47.3 million, but adjusted EBITDA was a $3.5 million loss due to elevated customer acquisition costs and the $39 introductory weight-management offer.
LifeMD reduced its full-year 2026 outlook to revenue of $205.5 million–$212.5 million and adjusted EBITDA ranging from a $6 million loss to breakeven, while the XYOSTED launch is expected to require $2 million–$3 million of investment this year.
Underlying business economics improved, with recurring-bill revenue at approximately 84% of total revenue, gross margin expanding to 89%, and sequential reductions of $1.8 million in advertising and $1.5 million in G&A expenses.
The $39 weight-management offer shifted new patients toward longer-duration plans, with multi-month selections rising from roughly 25% to 85%; management said recent acquisition costs were about 50% below their June peak.
Management expects adjusted EBITDA profitability in Q3 and Q4 revenue of $60 million–$64 million with adjusted EBITDA of $3 million–$6 million, supported by women’s health growth, pharmacy expansion, insurance initiatives, and new pharmaceutical partnerships.

LifeMD Stock Down 5.6%

Shares of LFMD stock traded down $0.22 during mid-day trading on Wednesday, reaching $3.68. 1,822,992 shares of the company’s stock traded hands, compared to its average volume of 689,328. The company’s 50-day moving average price is $4.43 and its 200-day moving average price is $3.98. The company has a market cap of $177.96 million, a P/E ratio of 73.61 and a beta of 2.02. LifeMD has a 12 month low of $2.56 and a 12 month high of $7.95.

Institutional Investors Weigh In On LifeMD

Hedge funds have recently bought and sold shares of the business. Tower Research Capital LLC TRC increased its stake in shares of LifeMD by 110.4% during the second quarter. Tower Research Capital LLC TRC now owns 4,674 shares of the company’s stock valued at $64,000 after purchasing an additional 2,452 shares in the last quarter. Quarry LP bought a new position in LifeMD during the 3rd quarter valued at approximately $52,000. Legal & General Group Plc raised its stake in LifeMD by 187.4% during the second quarter. Legal & General Group Plc now owns 10,144 shares of the company’s stock valued at $138,000 after buying an additional 6,614 shares during the last quarter. Caitong International Asset Management Co. Ltd purchased a new position in LifeMD during the fourth quarter valued at $36,000. Finally, Hudson Bay Capital Management LP bought a new stake in LifeMD in the second quarter worth $153,000. Institutional investors own 35.52% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on LFMD. HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of LifeMD in a research report on Tuesday, May 26th. Wall Street Zen downgraded LifeMD from a “hold” rating to a “sell” rating in a report on Saturday, July 18th. Weiss Ratings raised LifeMD from a “sell (e+)” rating to a “sell (d)” rating in a research note on Thursday, May 7th. BTIG Research reissued a “buy” rating and set a $10.00 price objective on shares of LifeMD in a research report on Monday, May 4th. Finally, Zacks Research downgraded shares of LifeMD from a “hold” rating to a “strong sell” rating in a research report on Friday, July 17th. Eight analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company. Based on data from MarketBeat, LifeMD presently has a consensus rating of “Moderate Buy” and an average target price of $9.14.

Check Out Our Latest Report on LifeMD

LifeMD Company Profile

(Get Free Report)

LifeMD (NASDAQ: LFMD) is a U.S.-based telehealth company that delivers on-demand, membership-based virtual healthcare services. Through its digital platform and mobile applications, LifeMD connects patients with board-certified healthcare providers for diagnosis, treatment and ongoing management of a range of acute and chronic conditions. The company’s core offering centers on personalized care plans supported by prescription fulfillment, lab testing and prescription delivery services.

LifeMD’s service portfolio spans several specialty areas, including men’s health, hormonal therapy, weight management and primary care.